Last updated: April 12, 2024
Sponsor: Egymedicalpedia
Overall Status: Active - Recruiting
Phase
1/2
Condition
Hair Loss
Alopecia
Treatment
Latanoprost
Clinical Study ID
NCT06239324
Maha Nabil
Ages 30-35 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients of both sexes with localized stable alopecia areata of the scalp of 3 monthsduration at least.
Exclusion
Exclusion Criteria:
- Acute or chronic infections.
- Pregnant or lactating women.
- Scarring alopecia.
- Alopecia totalis , Alopecia universalis and ophiasis.
- Autoimmune dermatological diseases.
Study Design
Total Participants: 70
Treatment Group(s): 1
Primary Treatment: Latanoprost
Phase: 1/2
Study Start date:
February 01, 2024
Estimated Completion Date:
May 01, 2024
Study Description
Connect with a study center
Qena Hospital
Qinā,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.